Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Interim results from the phase 1B and phase 2 Torrey open-label extension study of seralutinib in pulmonary arterial hypertension

Monday, November 11, 2024 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The interim results from the phase 1B and phase 2 Torrey open-label extension study indicate that seralutinib may be effective in treating pulmonary arterial hypertension (PAH). The study is ongoing and aims to evaluate the drug's safety and efficacy. These findings could lead to improved treatment options for patients suffering from PAH.
Price reaction · baseline $0.8582 (2024-11-11 close) · hit after-hours · 3 other GOSS headline(s) in the window, move may be shared
day 0 close · peak
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Interim results show promise for seralutinib in treating PAH.
  • The study is progressing through phases 1B and 2 effectively.
  • Potential for seralutinib to improve patient outcomes in pulmonary arterial hypertension.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Interim results from the phase 1B and phase 2 Torrey open-label extension study of seralutinib in pulmonary arterial hypertension
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What is seralutinib used for?

Seralutinib is being studied for its potential to treat pulmonary arterial hypertension (PAH).

What phases are included in the Torrey study?

The Torrey study includes phase 1B and phase 2 trials.

What are the results of the Torrey study?

The interim results indicate that seralutinib may be effective in treating PAH.

Is the Torrey study ongoing?

Yes, the study is currently ongoing and evaluating seralutinib's safety and efficacy.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare seralutinib pulmonary arterial hypertension phase 1B phase 2
Last updated: Nov 11, 2024

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →